Search by Drug Name or NDC
NDC 55513-0504-50 LUMAKRAS 320 mg/1 Details
LUMAKRAS 320 mg/1
LUMAKRAS is a ORAL TABLET, COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amgen Inc. The primary component is SOTORASIB.
MedlinePlus Drug Summary
Sotorasib is used to treat a certain type of lung cancer (non-small cell lung cancer; NSCLC) that has spread to other parts of the body or cannot be removed by surgery in adults who have received at least one other treatment. Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
Related Packages: 55513-0504-50Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Sotorasib
Product Information
| NDC | 55513-0504 |
|---|---|
| Product ID | 55513-504_336c6783-a078-4639-ba70-b59fdc55ce43 |
| Associated GPIs | |
| GCN Sequence Number | 084482 |
| GCN Sequence Number Description | sotorasib TABLET 320 MG ORAL |
| HIC3 | V5A |
| HIC3 Description | ANTINEOPLASTIC - KRAS PROTEIN INHIBITOR |
| GCN | 53809 |
| HICL Sequence Number | 047400 |
| HICL Sequence Number Description | SOTORASIB |
| Brand/Generic | Brand |
| Proprietary Name | LUMAKRAS |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | sotorasib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, COATED |
| Route | ORAL |
| Active Ingredient Strength | 320 |
| Active Ingredient Units | mg/1 |
| Substance Name | SOTORASIB |
| Labeler Name | Amgen Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA214665 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 55513-0504-50 (55513050450)
| NDC Package Code | 55513-504-50 |
|---|---|
| Billing NDC | 55513050450 |
| Package | 1 BOTTLE, PLASTIC in 1 CARTON (55513-504-50) / 90 TABLET, COATED in 1 BOTTLE, PLASTIC |
| Marketing Start Date | 2023-02-02 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |